Treating Chronic Hepatitis C

Victrelis (boceprevir) has been approved by the US Food and Drug Administration for the treatment of chronic hepatitis C combined with pegylated interferon alfa and ribavirin. Victrelis is the first of a new class of antiviral protease inhibitors. This medicine binds to hepatitis C virus to prevent its breeding. The safety and efficacy of Victrelis was evaluated in two Phase III clinical trials covering a total of 1,500 adult patients. In both trials, hepatitis C virus was no longer detected as two thirds of patients with Victrelis and peginterferon and ribavirin experienced a significant increase in persistent virologic response.

Sovaldi used in conjunction with other antiviral drugs to treat hepatitis C is a prescription drug for the treatment of chronic hepatitis C in adults, treatment of hepatitis genotype 1, 2, 3 C It is known to help treatment. Sofosbuvir or brand name Sovaldi will fight HCV and prevent proliferation in the body. Therefore, treatment of infectious diseases

Several drugs are available for treatment of chronic hepatitis C Recently, the treatment of hepatitis C has been greatly improved. Current treatments usually require only 8 to 12 weeks of oral treatment (pills) to cure 90% or more of people with fewer side effects. For a complete list of currently approved options for treatment of hepatitis C, please visit http://www.hepatitisc.uw.edu/page/ treatment / drugs. First of all, even if people with chronic hepatitis C had been treated for hepatitis C in the past, it is necessary to consult a doctor about treatment. For people with liver cirrhosis, there is a risk of persistent liver cancer even after hepatitis C virus infection has cured. Patients with chronic hepatitis C and liver cirrhosis (even if hepatitis C has recovered) are regularly monitored by the doctor and should receive immunization with hepatitis A and hepatitis B. Because patients with chronic hepatitis C may cause additional liver damage, avoid drinking.

Hepatitis C is a virus that causes acute and chronic hepatitis. More than 80% of people suffering from hepatitis C suffer from chronic hepatitis. Long-term infection of hepatitis C has a higher risk of cirrhosis and liver cancer. No effective vaccine to prevent hepatitis C has been developed. There is only one type of antiviral drug that can be used to treat hepatitis C. A combination of peginterferon alfa and ribavirin can be used to treat hepatitis C, but only about 30% to 50% of what is treated does not fully recover from this infection.